HK1200314A1 - R(+)-n-methyl-propargyl-aminoindan - Google Patents

R(+)-n-methyl-propargyl-aminoindan Download PDF

Info

Publication number
HK1200314A1
HK1200314A1 HK15100234.9A HK15100234A HK1200314A1 HK 1200314 A1 HK1200314 A1 HK 1200314A1 HK 15100234 A HK15100234 A HK 15100234A HK 1200314 A1 HK1200314 A1 HK 1200314A1
Authority
HK
Hong Kong
Prior art keywords
aminoindan
propargyl
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HK15100234.9A
Other languages
English (en)
Chinese (zh)
Inventor
Safadi Muhammad
Frenkel Anton
Keisar Michal
Licht Danit
Bahar Eliezer
Lidor-Hadas Ramy
Zholkovsky Marina
Cohen Rachel
Original Assignee
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceuticals Usa, Inc.
Publication of HK1200314A1 publication Critical patent/HK1200314A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15100234.9A 2011-10-10 2012-10-09 R(+)-n-methyl-propargyl-aminoindan HK1200314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545426P 2011-10-10 2011-10-10
US61/545,426 2011-10-10
PCT/US2012/059358 WO2013055689A1 (en) 2011-10-10 2012-10-09 R(+)-n-methyl-propargyl-aminoindan

Publications (1)

Publication Number Publication Date
HK1200314A1 true HK1200314A1 (en) 2015-08-07

Family

ID=48042233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100234.9A HK1200314A1 (en) 2011-10-10 2012-10-09 R(+)-n-methyl-propargyl-aminoindan

Country Status (15)

Country Link
US (1) US9339469B2 (https=)
EP (1) EP2766004A4 (https=)
JP (1) JP2014534197A (https=)
KR (1) KR20140084153A (https=)
CN (1) CN103930100A (https=)
AR (1) AR088766A1 (https=)
AU (1) AU2012323351A1 (https=)
BR (1) BR112014008552A2 (https=)
CA (1) CA2851433A1 (https=)
EA (1) EA201490760A1 (https=)
HK (1) HK1200314A1 (https=)
IL (1) IL231722A0 (https=)
MX (1) MX2014004201A (https=)
WO (1) WO2013055689A1 (https=)
ZA (1) ZA201403050B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
ITUB20160650A1 (it) * 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
CN111983075A (zh) * 2020-08-17 2020-11-24 重庆华森制药股份有限公司 一种检测雷沙吉兰及其对映异构体的方法
CN116550007B (zh) * 2023-04-24 2026-03-06 江苏汉邦科技股份有限公司 一种利用超临界流体色谱系统分离制备4-氨基茚满的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
EP1954667B1 (en) 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
JP5356248B2 (ja) 2006-12-14 2013-12-04 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンのタンニン酸塩
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090181086A1 (en) 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
JP2013507352A (ja) 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
US20120101168A1 (en) 2010-10-26 2012-04-26 Eliezer Bahar Deuterium enriched rasagiline
CN103857389A (zh) 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Also Published As

Publication number Publication date
ZA201403050B (en) 2015-08-26
AR088766A1 (es) 2014-07-02
WO2013055689A8 (en) 2014-04-10
CN103930100A (zh) 2014-07-16
CA2851433A1 (en) 2013-04-18
MX2014004201A (es) 2015-01-12
KR20140084153A (ko) 2014-07-04
BR112014008552A2 (pt) 2017-04-18
WO2013055689A1 (en) 2013-04-18
EA201490760A1 (ru) 2014-09-30
AU2012323351A1 (en) 2014-05-22
US9339469B2 (en) 2016-05-17
EP2766004A4 (en) 2015-04-22
EP2766004A1 (en) 2014-08-20
JP2014534197A (ja) 2014-12-18
IL231722A0 (en) 2014-05-28
US20130089610A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
HK1200313A1 (en) Rasagiline citramide
HK1200315A1 (en) R(+)-n-formyl-propargyl-aminoindan
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012087288A3 (en) Metal salt compositions
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
WO2012158843A3 (en) Kinase inhibitors
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
IN2014CN03506A (https=)
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2012006538A8 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
IN2015DN00598A (https=)
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2011163636A3 (en) Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
IN2014DN07996A (https=)
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
WO2012064743A3 (en) Methods for improving heart function
WO2013169746A3 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
IN2014DN10669A (https=)
GB201020397D0 (en) Compounds